Introduction Epithelial ovarian cancer (EOC) is recognised to be heterogeneous but is currently treated with a single treatment strategy. Successful patient stratification of emerging chemotherapy agents is dependent upon the availability of reliable biomarkers indicative of the entire tumour.
Introduction
The term ovarian cancer describes a set of distinct and heterogeneous diseases, all of which are currently treated with a single treatment regimen. Despite advances in surgery and the addition of taxane to platinum chemotherapy, the 5-year survival has remained low at 30-40%. Improved outcomes will require the use of targeted agents and novel cytotoxic agents exploiting the molecular pathology of the tumour.
Reliable molecular predictive biomarkers are still lacking for ovarian cancer. The classification of epithelial ovarian cancer into histological types (high grade serous, endometrioid, clear cell, mucinous and low grade serous), associated with different driver mutations, is well established but more recent work has taken this further and subdivided high grade serous cancer using genomic [1] , gene expression [2] and functional [1, 3] techniques. This has generated at least four distinct gene expression subgroups [2, 4] with diverse prognostic behaviour. This approach however has not yet successfully identified a reliable gene signature capable of predicting actual response to cytotoxic agents. Subdivision into groups according to overall function of a DNA repair pathway (homologous recombination) [3] is not related to histological subgroup and has potential to enable stratification of patients according to differences in their sensitivity to conventional and novel chemotherapy agents [5, 6] .
To date, systemic treatment for epithelial ovarian cancer has been platinum based, irrespective of histological subtype or other biological markers. An increased understanding of the disease combined with the development of new, targeted, agents is changing this model and allowing the development of personalised medicine. However, effective delivery of novel agents and the correct selection of patients will require the use of accurate biomarkers capable of predicting response and there is great interest in developing these from both academia [7] and industry [8] . Ovarian cancer typically presents at a disseminated stage with multiple sites of disease within the peritoneal cavity and elsewhere. Unless tumours are homogeneous it is likely that biopsies from a single site of a tumour may not be representative of the rest of the tumour and therefore be unable to predict response accurately. In particular, most biopsies used for clinical diagnosis are taken from the omentum under radiological guidance. It is rare for disease on the diaphragm or nodal disease to be sampled. Given that there may be biological differences between disease which disseminates within the peritoneal cavity, through direct spread, compared to disease that disseminates by a classical process using lymphatic or haematogenous spread [9] it is likely that there could be a systematic bias in reporting of biopsies. There is no published evidence demonstrating radiological variable response to chemotherapy within an individual patient across different tumour sites but this is likely to reflect a lack of studies. RECIST criteria take into account measured response in both target and non-target lesions giving an overall response rather than documentation of individual lesions by anatomical site. As molecular data taken from biopsies start to be used to direct therapy both in clinical trials and in clinical practice, knowledge of heterogeneity between intra-abdominal sites becomes increasingly important. Genetic intra-tumoural heterogeneity has been demonstrated but the question of functional heterogeneity and subsequent response to therapy has not been addressed in any prospective study.
Intra-tumoural heterogeneity can currently be assessed using morphological classification or analysis of genetic mutations. The histological subtypes of epithelial ovarian cancer have distinct and different pathogenetic processes [10] with variable response to therapy but true morphological heterogeneity is relatively rare in ovarian cancer and it has been suggested that this is overdiagnosed [11] . This suggests that histology alone is not sensitive enough to detect changes in underlying tumour biology. . There is general consensus that most cases of ovarian cancer are monoclonal in origin with a high degree of genomic parsimony but significant heterogeneity exists within microsatellites and SNPs [12] and copy number changes and driver mutation status [13] from anatomically distinct regions. This does not appear to translate into a significant degree of heterogeneity in terms of gene expression [14] .
Other possible mechanisms of heterogeneity, including epigenetic changes in methylation, which is known to be important in determining functional status of the tumour, have not been studied.
There is therefore evidence that significant ITH is likely to exist but how this knowledge can be employed to provide prediction to treatment is less clear.
Cancers develop heterogeneity as a result of a process of somatic evolution but many of the mutations that occur have no functional effect and are termed passenger mutations. It may be more clinically relevant to examine the functional effects of heterogeneity rather than just relying on genomic variation. For this reason we have developed functional assays for homologous recombination DNA repair (HR) [15, 16] .
The aim of this study was to evaluate the extent of intra-and inter-tumour heterogeneity within a series of ovarian cancers using homologous recombination DNA repair status as a biomarker, and consider the potential impact of heterogeneity upon response to treatment and the subsequent management of such disease.
Materials and Methods

Reagents
Rucaparib was a gift from Clovis (Boulder, USA) and is a potent inhibitor of PARP-1 and -2 proteins (Ki <5 nM). Rucaparib was dissolved in DMSO to give a stock solution of 10 mM, which was stored at −20 °C for in vitro studies. Cisplatin (Alexis Biochemicals, California USA) is a potent antineoplastic drug which forms inter-and intra-strand DNA adducts. Cisplatin was dissolved in water to give stock solution of 2 mM, which was stored at -20 °C. All other chemicals and tissue culture reagents were from Sigma-aldrich (Sigma-aldrich, UK), unless otherwise stated.
Cell Culture
Sample collection
Ethical approval was granted (12/NW/0202) for the collection of ascites and solid tissue from consented patients undergoing surgery for ovarian cancer at the Queen Elizabeth Hospital, Gateshead, UK. Samples were collected between 02/2012 and 08/2013 from patients recruited with radiological evidence of pelvic masses suspicious for or confirmed to be an ovarian malignancy. Clinical details were recorded and specimens registered and handled in accordance with the Human Tissue Act. Samples were assigned a PCO (Primary Culture Ovary) reference number to retain anonymity. All samples were handled separately with their own reagents to prevent crosscontamination.
Sample transport and preparation
Ascitic fluid was aspirated directly from the patient into a sterile suction bottle. Solid tumour specimens of approximately 1 cm 3 were excised from surgical specimens and from any areas of irresectable tumour intra-operatively. The sample site was carefully documented and the solid tumour was placed into a sterile universal containing culture medium (RPMI 1640 medium supplemented with 10% FCS, 20mM L-glutamine and 1% penicillin and streptomycin) pre-warmed to 37C. Samples were transported from the hospital to the lab immediately in compliance with UK Category B regulations UN3373.
Ascitic cell culture
Cell culture was performed using an aseptic technique in a containment level II laminar flow microbiological safety cabinet, as previously described [17] . Briefly, 20 ml of ascitic fluid was added to 20 ml of warmed culture medium (RPMI 1640 medium supplemented with 10% FCS, 20 mM Lglutamine and 1% penicillin and streptomycin) in T75 flasks (Corning, NY) and incubated at 37°C, 5%
CO2, 95% humidified air. The medium was aspirated and 13 ml of warmed fresh medium was replaced on day 3 to 5. When confluence was approached cells were passaged, frozen and thawed as previously described [18] .
Primary culture from solid tumour
Solid culture was performed using techniques previously described [17] . Briefly, 1 cm 3 solid tumour collected from intra-abdominal sites during cytoreductive surgery and transported to the lab in 
Morphology
Morphological features of cells in culture were studied under an Olympus CK40 inverted microscope at 20X magnification and images were captured using VisiCam® software (VWR, USA). Cultures were classified as having cobblestone, spindle or mesenchymal morphology.
Immunofluorescence
Standard techniques for immunofluorescence were used to stain for six epithelial, mesenchymal, and ovarian markers, Error! Reference source not found.. Cells were grown on coverslips, fixed with ice cold methanol prior to incubation with primary antibody. All cultures were assessed for antigen expression at passage 1. A panel of markers was used in the absence of a single specific epithelial ovarian marker. Cultures were deemed to be non-epithelial if they failed to demonstrate expression of either cytokeratin, MOC31 or EpCam and were discarded.
Formal histopathology
Formal cytological and histopathological examination of matched ascites and solid tumour specimens from every patient was performed and using standard techniques used to further characterise the cultures. This was performed by an independent expert pathologist blinded to the results of the antigen expression studies. Specimens were assigned to an ovarian histological subtype according to universal World Health Organisation criteria [19] .
When all characteristics were in keeping with epithelial ovarian origin, the samples were then used in subsequent experiments, at either passage 1 or 2. Cultures were discarded after passage 2. Where results were inconsistent with epithelial origin, cultures were discarded.
Growth and Cell Proliferation assays
A routine sulforhodamine B (SRB) assay was used to assess cytotoxicity and cell growth as previously described [20] . Briefly, cells were seeded at a density of 1000 cells/well and after adherence, treated with various concentrations of rucaparib (0, 0.1, 1, 10, 50, 100 μM) or cisplatin (0, 0.01, 0.03, 0.1, 0.3, 1, 3, 10 μM) for 10 days before fixation. For assessment of growth, cells were seeded, as above, then fixed at 24 hour intervals before staining and spectrophotometer assessment of cell density.
The equation (t2 -t1)/3.32 x (log n2 -log n1) was used to caluclate doubling time, where t = time and n= cell density.
Homologous recombination assay
HR functional status was determined using a previously described method [16] . This assay quantifies Cells were seeded onto uncoated glass cover slips and treated with 2 Gy ionising radiation and rucaparib at 10 µM concentration for 24 hours to induce double strand breaks (DSB) [15] . All experiments were performed alongside untreated controls with equivalent 0.1% DMSO. Cells were then fixed and rehydrated prior to staining with 1:100 mouse monoclonal anti-γH2AX (Upstate, Millipore Corp., USA) and 1:100 goat polyclonal anti-Rad51 (Calbiochem, EMD Biosciences, Inc.)
antibodies with appropriate secondary fluorochrome conjugated antibodies, as previously described [16] .
Image J counting software [21, 22] was used to count γH2AX and Rad51 nuclear foci across three microscope fields for both treated (DNA damage induced) and control cells. The average number of foci per cell was expressed as percentage of untreated controls. Reliability, reproducibility, and validity of our data were confirmed by repeated tests across different fields, comparison of two counting methods (manual and software), and counting by two independent reviewer. Cells were classed as HR competent if there was more than a 2 fold increase in Rad51 foci after DNA damage, confirmed by a 2 fold increase in γH2AX [15] .
Results
Patient demographics
Patient demographics for patients with solid and ascitic cultures are summarised in Table 2 . In total PCO cultures from ascites with matched solid tumour were cultured from 25 patients. Collection was not restricted by histological subtype or collection at primary surgery only ensuring all patterns of heterogeneity were captured. Solid tumour was sampled from pelvic tumour only in 13 patients and in pelvic and intra abdominal deposits for the remaining 12 patients, giving an overall total of 68 cultures.
Intra-tumour heterogeneity of HR functional status
When considered individually, of the 68 subcultures tested, 32 (47.1%) were HR competent and 36 (52.9%) were HR defective, supplementary 
Histological classification or characterisation of protein expression by immunohistochemistry or immunofluorescent microscopy has no clinical relevance in terms of response to therapy
All subcultures were characterised in terms of morphology and classified as cobblestone, spindle cell or mesenchymal phenotype, Figure 1 . In addition to morphology of actual cultures formal histopathological examination, supplemented with immunohistochemistry, of matched FFPE samples was also performed. The majority of the cohort (19/25, 76%) had high grade serous disease with a cobblestone monolayer appearance and almost all (23/35, 92%) had homogenous histology.
Inter-and intra-tumour heterogeneity was seen between the expression of epithelial and ovarian markers using the immunoflourescent characterisation panel, 2. The majority of the tumours showed expression of epithelial as well as mesenchymal markers using both techniques. Vimentin expression was universal throughout all subcultures.
PCO samples taken from nine patients showed completely homogeneous staining patterns between all subcultures from the same patient with no difference in expression of any markers between ascitic and solid subcultures for epithelial, mesenchymal or ovarian markers.
However for 16 patients there was non concordance between at least one of the markers. With the exception of vimentin, concordance rates decreased as the number of samples analysed for each patient was increased from two (ascites and one solid sample) to three (ascites and two paired solid samples), Table 3 . 
Sensitivity to cisplatin and rucaparib correlates with HR functional status
Sensitivity to rucaparib and cisplatin was assessed for 59/68 subcultures generated. There was 84.7% concordance between HR status and rucaparib sensitivity and 75.5% concordance between HR status and platinum sensitivity. When subcultures are grouped together according to HR function, HR defective cultures were sensitive to both cisplatin and rucaparib with mean GI50 of 4.02 µM and 9.73 µM respectively; compared to HR competent cultures, with mean GI50 of >10 µM and >100µM, (p < 0.0001), 4.
Discussion
In this study we add to current evidence of inter-tumourol heterogeneity in ovarian cancer in terms of antigen expression and proliferation rate, and DNA repair HR function from ascites. Additionally, We have previously demonstrated a very strong correlation between HR status and ex vivo sensitivity to the PARP inhibitor rucaparib using cells cultured from just one compartment, namely ascites [16] with responses seen in approximately 50% of cases [3] . In clinical practice however, response rates to olaparib in non germline BRCA 1 and 2 patients are only 24% [25] . This may be a result of underlying heterogeneity at presentation and subsequent clonal selection pressure as a result of initial chemotherapy.
The demonstration in this study that the results of predictive biomarkers will be affected by intra tumour heterogeneity has ramifications for future translational research and biomarker directed therapy. It is crucial that future studies include multiple biopsies to allow assessment of intra tumour heterogeneity and that protocols which require sequential biopsies taken before and after treatment attempt to collect these biopsies from the same tumour site to minimise the risk of selecting non paired clones.
Further work is required to extend this work. In particular correlation of heterogeneity with disease location (intra peritoneal versus extra peritoneal) would provide insight into the biology of the metastatic process in ovarian cancer. 
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